Surrozen Inc Quick Ratio (SRZN) starting from the third quarter 2026 to third quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Surrozen Inc   (NASDAQ: SRZN)

Surrozen Inc 's Quick Ratio

SRZN's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the third quarter 2026, Quick Ratio fell to 0.35 below Surrozen Inc average.

Within Biotechnology & Pharmaceuticals industry 125 other companies have achieved higher Quick Ratio than Surrozen Inc in third quarter 2026. While Quick Ratio total ranking in the third quarter 2026 has deteriorated compared to the prior quarter from 2545 to 2629.

Explain Quick Ratio?
How much Cash & cash equivalents SRZN´s has?
What are SRZN´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

SRZN Quick Ratio (Sep 30 2026)
Q3		 (Jun 30 2026)
Q2		 (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3
Y / Y Current Liabilities Change 403.53 % 1215.98 % 369.28 % 2187.11 % 830.31 %
Y / Y Cash & cash equivalent Change 23.38 % 12.89 % 5.18 % 158.19 % 162.27 %
Quick Ratio MRQ 0.35 0.5 0.44 0.53 1.43
SRZN's Total Ranking # 2629 # 2545 # 0 # 1370 #
Seq. Current Liabilities Change 41.02 % -16.39 % 45.34 % 193.85 % 268.56 %
Seq. Cash & cash equivalent Change -1.65 % -4.56 % 19.79 % 9.73 % -10.02 %



Quick Ratio third quarter 2026 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 126
Healthcare Sector # 742
Overall Market # 2629


Quick Ratio Statistics
High Average Low
23.72 7.03 0.44
(Mar 31 2021)   (Mar 31 2026)




Financial Statements
Surrozen Inc 's Current Liabilities $ 287 Millions Visit SRZN's Balance sheet
Surrozen Inc 's Cash & cash equivalent $ 100 Millions Visit SRZN's Balance sheet
Source of SRZN's Sales Visit SRZN's Sales by Geography


Cumulative Surrozen Inc 's Quick Ratio

SRZN's Quick Ratio for the trailling 12 Months

SRZN Quick Ratio

 (Sep 30 2026)
12 Months		 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 584.67 % 731.1 % 577.83 % 1038.81 % 417.16 %
Y / Y Cash & cash equivalent TTM Growth 29.43 % 47.33 % 79.47 % 177.59 % 133.09 %
Quick Ratio TTM 0.44 0.57 0.76 1.24 2.34
Total Ranking TTM # 3987 # 3106 # 0 # 3202 #
Seq. Current Liabilities TTM Growth 34.26 % 38.9 % 65.64 % 121.65 % 62.97 %
Seq. Cash & cash equivalent TTM Growth 5.01 % 3.17 % 1.45 % 17.76 % 19.53 %

Quick ratio ranking by company, industry and sector >> Back to SRZN Financial Strength Comparisons >> Go to Compare SRZN Quick Ratio to its Competitors

On the trailing twelve months basis Due to jump in Current Liabilities in the Q3 2026 to $286.68 millions, cumulative Quick Ratio decreased to 0.44 below the Surrozen Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 142 other companies have achieved higher Quick Ratio than Surrozen Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 3106 to 3987.

Explain Quick Ratio?
How much Cash & cash equivalents SRZN´s has?
What are SRZN´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 143
Healthcare Sector # 899
Within the Market # 3987


trailing twelve months Quick Ratio Statistics
High Average Low
6.14 3.16 0.24
(Sep 30 2021)   (Mar 31 2021)




Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Biotechnology & Pharmaceuticals Industry Quick RatioSep 30 2026 MRQ Cash & cash equivalentSep 30 2026 MRQ Current Liabilities
C4 Therapeutics Inc   0.81 $ 33.492  Millions$ 41.460  Millions
Allogene Therapeutics Inc   0.76 $ 29.270  Millions$ 38.498  Millions
Ocugen Inc   0.71 $ 84.257  Millions$ 118.901  Millions
Neurocrine Biosciences Inc   0.59 $ 739.100  Millions$ 1,242.800  Millions
Iovance Biotherapeutics inc   0.55 $ 57.934  Millions$ 105.774  Millions
Agenus Inc  0.43 $ 86.936  Millions$ 203.691  Millions
Vaxcyte Inc   0.42 $ 125.470  Millions$ 295.697  Millions
Vaxart Inc   0.41 $ 30.435  Millions$ 73.934  Millions
Surrozen Inc   0.35 $ 100.353  Millions$ 286.684  Millions
Biogen Inc   0.16 $ 628.100  Millions$ 3,898.400  Millions

Date modified: 2026-11-10T06:58:35+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.